I’m thrilled to announce this TechCrunch Live event. The startup Cambrian BioPharma is developing a life-changing technology while pioneering a radical approach to a pharmaceutical company. Don’t miss this TechCrunch Live happening on May 3 at 12 p.m. PDT. Register here. It’s free to look at and participate.
Cambrian BioPharma bills itself as a latest pharmaceutical company with a revolutionary approach to developing and managing drug development. James Peyer, PhD, co-founded the corporate in 2019, and it has since raised over $180 million to speed up the event of drugs designed to focus on the causes of age-related diseases.
But that’s not essentially the most interesting part. Peyer’s executive team has managed to draw top talent by giving them an oversized amount of equity in comparison with traditional pharmaceutical corporations. As a substitute of developing pharmaceuticals inside Cambrian BioPharma, the corporate essentially spins out the answer with the highest scientists sitting within the C-suite alongside seasoned Cambrian BioPharma executives who will help operate the brand new company.
Maryanna Saenko of Future Ventures can be speaking at this TechCrunch Live event. She sits on Cambrian BioPharma’s board of directors and invested in the corporate’s Series A, B, and C rounds. Together, the 2 are going to interrupt down Cambrian BioPharma’s unique business model and explain why this process works so well.
Maryanna can be a co-founder and partner at Future Ventures, where she sits on the boards of several deep tech medical startups, including Deep Genomics, Earthshot Labs, and Gameto. She brings along with her a wealth of information and experience from her time at Future Ventures, and previously Khosla Ventures, Threshold Ventures, and DFJ. It’s a joy to have her and James Peyer speak on the revolutionary work of Cambrian BioPharma.
